The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes

Albisinni, Simone; Prétot, Dominique; Obeid, Walid Al Hajj; Aoun, Fouad; Quackels, Thierry; Peltier, Alexandre; Roumeguère, Thierry

doi:10.1016/j.purol.2019.05.008

Cited by 17 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of prognostic value of baseline PLR in the current analysis is in contrast to previous studies in advanced RCC where elevated PLR was prognostic for shorter progression-free survival, overall survival, recurrence-free survival and cancer-specific survival, compared with lower PLR levels [4][5][6][10][11][12][13][14][15]. This may reflect intrinsic study differences in patient inclusion criteria, differences in type of inflammation (inflammation associated with tumor volume vs postsurgical inflammation), treatment setting (nonadjuvant vs adjuvant), the use of DFS as the treatment end point and study power.…”

Section: Discussioncontrasting

confidence: 99%

Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting

Patel¹,

Ravaud

Motzer

et al. 2020

Future Oncol.

View full text Add to dashboard Cite

Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7–1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6–1.0). Conclusion: Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 ( ClinicalTrials.gov )

show abstract

Section: Discussioncontrasting

confidence: 99%

Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting

Patel¹,

Ravaud

Motzer

et al. 2020

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…Meanwhile, neutrophils secrete IL-6, vascular endothelial growth factor (VEGF), and transforming growth factor beta (TGF-β) in the tumor microenvironment, resulting in the induction of lymphocyte apoptosis and immunosuppression (26). Albisinni et al also suggest NLR and HPR seem closely related to the RFS, CSS and OS in bladder cancer (27). Platelets also play an important role in the recruitment and regulation of monocytes and granulocytes into tumor lesions (13), suggesting that platelet functionality may be critical for the production of tumor-associated macrophages and tumor-associated neutrophils (28).…”

Section: Discussionmentioning

confidence: 99%

Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy

Zhang¹,

Yang²,

Kadier³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Bladder cancer is one of the most common carcinomas and it brings about huge social economic burden. There is not a reliable way to predict the prognosis of bladder patients. We develop the nomogram to predict the prognosis of bladder cancer patients.Methods: A total of 127 bladder cancer patients after radical cystectomy were studied retrospectively. Their clinicopathological data were collected for statistical analysis.Results: The level of albumin/globulin ratio (AGR), C-reactive protein/albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) associated with pathological and hematological parameters like T stage and hemoglobin. Furthermore, the AGR was associated with overall survival (OS) and CAR, NLR, and PLR were associated with both OS and progression-free survival (PFS) (P<0.05). The multivariate analysis revealed that tobacco smoking, tumor T stage, M stage, NLR, CAR, and AGR were all independent predictors for OS of patients and tobacco smoking, tumor T stage, NLR, CAR, and AGR were independent predictors for PFS of patients. In addition, AGR, CAR, and NLR, as well as, the clinicopathological parameters in the development of nomograms with a C index of 0.901 (95% CI: 0.505-1.269) for OS, and 0.807 (95% CI: 0.755-0.858) for PFS. The nomograms were able to provide a prognosis of the OS with the area under the curve (AUC) =0.86. Further, tests assessed the PFS with the AUC =0.84.Conclusions: This study demonstrates that the nomograms of the inflammatory biomarkers were able to predict prognosis of bladder cancer patients after radical cystectomy.

show abstract

“…Albisinni et al. ( 34 ) reported that localized RCC patients with elevated NLR were more likely to present with ≥ pT3 stage. As noted above, it appears apparent that laboratory test results may be related to the presence of pT3a upstaging.…”

Section: Discussionmentioning

confidence: 99%

“…The systemic inflammatory markers mainly involved three categories of indices: differential blood cell counts (i.e., monocytes, lymphocytes, platelets and neutrophils), concentration of specific serum proteins (i.e., CRP and albumin) and combinations of these indices (i.e., NLR, PLR, LMR and mGPS) (33). Albisinni et al (34) reported that localized RCC patients with elevated NLR were more likely to present with ≥ pT3 stage. As noted above, it appears apparent that laboratory test results may be related to the presence of pT3a upstaging.…”

Section: Discussionmentioning

confidence: 99%

Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a

et al. 2021

View full text Add to dashboard Cite

ObjectivesWe aimed to determine preoperative risk factors associated with pathologic T3a (pT3a) upstaging of clinical T1 (cT1) renal cell carcinomas (RCCs) and develop a novel model capable of accurately identifying those patients at high risk of harboring occult pT3a characteristics.MethodsA retrospective analysis of 1324 cT1 RCC patients who underwent partial nephrectomy (PN) or radical nephrectomy (RN) was performed. The study cohort was divided into training and testing datasets in a 70:30 ratio for further analysis. Univariable and multivariable logistic regression analyses were performed to identify predictors associated with cT1 to pT3a upstaging and subsequently, those significant risk factors were used to construct models. We used the area under the curve (AUC) to determine the model with the highest discrimination power. Decision curve analyses (DCAs) were applied to evaluate clinical net benefit associated with using the predictive models.ResultsThe rates of upstaging were 6.1% (n = 81), 5.8% (n = 54) and 6.8% (n = 27) in the total population, training cohort and validation cohort, respectively. Tumor size, clinical T stage, R.E.N.A.L. (radius, exophytic/endophytic properties, nearness of tumor to collecting system or sinus, anterior/posterior) nephrometry score, lymphocyte to monocyte ratio (LMR), prognostic nutrition index (PNI) and albumin to globulin ratio (AGR) were significantly associated with pT3a upstaging. The model that consisted of R.E.N.A.L. score, LMR, AGR and PNI achieved the highest AUC of 0.70 in the validation cohort and yielded the highest net benefit. In the subpopulation with complete serum lipid profile, the inclusion of low-density lipoprotein cholesterol (LDL-C) and Castelli risk index-I (CRI-I) significantly improved the discrimination of model (AUC = 0.86).ConclusionsOur finding highlights the importance of systemic inflammation response markers and serum lipid parameters in predicting pT3a upstaging. Our model had relatively good discrimination in predicting occult pT3a disease among patients with cT1 renal lesions, and the use of the model may be greatly beneficial to urologists in risk stratification and management decisions.

show abstract

The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes

Cited by 17 publications

References 34 publications

Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting

Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting

Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy

Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a

Contact Info

Product

Resources

About